Home / FINANCE / Markets Insider / BRIEF-Immune Pharmaceuticals’ Oncology subsidiary, Cytovia Inc. Provides refurbish to due pint pharma transaction

BRIEF-Immune Pharmaceuticals’ Oncology subsidiary, Cytovia Inc. Provides refurbish to due pint pharma transaction

June 29 (Reuters) – Immune Pharmaceuticals Inc

* Immune pharmaceuticals’ oncology subsidiary, cytovia inc. Provides update
to due pint pharma transaction: estimable agreement reached on material
terms of a chartering and commercialization of ceplene® in latin america

* Immune pharmaceuticals inc – estimable agreement reached on material
terms of chartering and commercialization of ceplene® in latin america

* Immune pharmaceuticals inc – parties now expect that they will
execute a decisive chartering agreement within subsequent 5 to 7 business days

* Immune pharmaceuticals inc – parties have concluded to enter into definitive
agreement associated to pint’s joining to deposit $4 million into cytovia

* Immune pharmaceuticals inc – “plan to pursue capitulation of ceplene in united
states formed on formerly announced tellurian altogether presence study, remain”

* Immune pharmaceuticals inc – massimo radaelli, executive authority of pint
will join house of directors of cytovia following execution of investment

* Immune pharmaceuticals – “plan is to commercialize ceplene in combination
with low sip il-2 in all markets that accept european registration dossier as a
basis for approval”
Source content for Eikon:
Further association coverage:

Leave a Reply

Your email address will not be published. Required fields are marked *

*

x

Check Also

San Francisco Public Utilities Commission, CA, Commerical Paper Notes (Water Series, Proposition E) Subseries A-1 & A-1-T, $200MM — Moody’s Assigns LOC-backed P-1 to SFPUC’s CP Notes A-3 &…

Rating Action: Moody’s Assigns LOC-backed P-1 to SFPUC’s CP Notes A-3 A-3-T; affirms P-1 on ...